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Abstract 
 
Background/Aim. KIT (KIT proto-oncogene receptor tyro-
sine kinase) and PDGFRA (platelet-derived growth factor re-
ceptor alpha) gene mutations represent major molecular forces 
inside the gastrointestinal stromal tumors (GIST). Aim of this 
study was to evaluate these mutations in the patients who un-
derwent surgical resection of gastric GIST, but without imati-
nib mesylate treatment. Methods. Retrospective clinical study 
included patients who were operated on due to gastric GIST 
from November 2000 till November 2016. A molecular analy-
sis of paraffin embedded tumor tissue was performed, and the 
patients with the presence of KIT and PDGFRA mutations 
were further evaluated, with regard to the pathological tumor 
stage, disease recurrence and overall survival. Results. Out of 
45 patients in total, 43 patients had KIT and PDGFRA muta-
tions, and 2 patients were classified as the wild type GIST. Af-
ter curative resection, 11 patients were classified as a low risk 
GIST, 8 as an intermediate risk and 26 as a high risk GIST. 
The KIT mutations were present in 37 patients, most com-
monly as deletion in exon 11. The PDGFRA mutations were 
present in 6 patients. The presence of KIT mutation had a 
strong statistical correlation with the mitotic index (p = 0.021). 
After the ten-year follow-up, all patients with the PDGFRA 
mutations were alive, while those with the KIT mutations had a 
survival rate of 71% (p = 0.31). Conclusion. The presence of 
KIT exon 11 deletion in the patients with primarily resected 
gastric GIST is associated with the higher mitotic index and 
worse overall survival than those present with the PDGFRA 
mutations. This results suggest prognostic significance towards 
more aggressive behaviors. 
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Uvod/Cilj. KIT (KIT proto-oncogene receptor tyrosine kinase) i 
PDGFRA (Platelet-derived growth factor receptor alpha) genske mutacije 
predstavljaju osnovne molekularne promene u grupi gastrointesti-
nalnih stromalnih tumora (GIST). Cilj ove studije bio je da se anal-
iziraju KIT i PDGFRA mutacije u grupi bolesnika koji su operisani 
zbog primarnog GIST-a želuca, ali bez terapije imatinib mesilatom. 
Metode. Načinjena je retrospektivna klinička studija koja je 
uključila bolesnike operisane zbog GIST-a želuca u periodu od 
novembra 2000. do novembra 2016. godine. Načinjena je moleku-
larna analiza na parafinskim kalupima tumorskog tkiva, a kod bo-
lesnika kod kojih su identifikovane KIT i PDGFRA mutacije 
sprovedena je dalja analiza, sa posebnim osvrtom na patološke ka-
rakteristike tumora, recidiv oboljenja i ukupno preživljavanje, te 
procena uticaja analiziranih genskih mutacija na navedene pro-
mene. Rezultati. Od ukupno 45 bolesnika, 43 bolesnika imala su 
prisutne mutacije na KIT i PDGFRA genima, dok su dva bolesni-
ka klasifikovani kao “wild type” GIST. Po učinjenoj kurativnoj re-
sekciji, 11 bolesnika je klasifikovano u grupu GIST-a niskog ste-
pena, 8 u grupu srednjeg, a 26 bolesnika u grupu visokog rizika od 
metastaziranja. KIT mutacije su bile prisutne kod 37 bolesnika, na-
jčešće u formi deleciji na egzonu 11. PDGFRA mutacije bile su 
prisutne kod 6 bolesnika. Prisustvo KIT mutacija imalo je visoku 
statističku korelaciju sa mitotiskim indeksom (p = 0,021). Nakon 
desetogodišnjeg praćenja, svi bolesnici iz grupe sa PDGFRA mu-
tacijama su bili živi, dok je stepen preživljavanja bolesnika sa KIT 
mutacijama iznosio 71% (p = 0,31). Zaključak. Prisustvo KIT eg-
zon 11 delecija kod bolesnika kod kojih je sprovedena primarna hi-
rurška intervencija zbog GIST-a želuca povezana je sa visokim mi-
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totskim indeksom i lošijem ukupnom preživljavanju, ali bez statis-
tički značajne razlike u odnosu na bolesnike kod kojih je bila pris-
utna PDGFRA mutacija. Ovi rezultati ukazuju na prognostički 
značaj u pravcu agresivnog ponašanja tumora. 
Ključne reči: 
gastrointestinalni stromalni tumori; geni; mutacija; 
hirurgija digestivnog sistema, procedure; neoplazme, 
metastaze; prognoza; preživljavanje. 
 
Introduction 
Gastrointestinal stromal tumor (GIST) represents a most 
common mesenchymal neoplasm of the digestive system 1. 
These tumors can be located in every part of alimentary tract, 
but most frequently GISTs are encountered in stomach 2. 
Gastrointestinal bleeding is leading symptom, followed 
with dyspepsia, abdominal pain and discomfort, but its pres-
entation can range from palpable masses in the abdomen to 
completely asymptomatic ones 3. Unlike the carcinomas, 
GISTs lack dominant infiltrative type of growth, and rarely 
can involve the lymph nodes. However, once these tumors 
have reached the malignant potential, very aggressive he-
matogenous spread may occur, predominantly affecting the 
liver. This malignant potential in GISTs is outlined by three 
major factors, tumor site (location), size, and mitotic rate, 
and the risk systems based on these factors: were proven and 
implemented in rutine clinical practice 4. Genetic alterations 
in GIST are relatively well-known, mostly through the as-
sessments of tyrosine kinases inhibitor KIT and the platelet-
derived growth factor receptor alpha (PDGFRA) gene muta-
tions. Both genes play crucial role in GIST pathogenesis, as 
their activation has significant influence on the cell prolifera-
tion, apoptosis and other important cell functions 5. 
Molecular changes in KIT and PDGFRA genes repre-
sent lead driving power in pathogenesis of gastrointestinal 
stromal tumors. These genes are the members of tyrosine ki-
nase receptors, type III 6, 7. With knowledge that kinase re-
ceptors play significant role in the treatment of GIST pa-
tients, proper understanding the mutations in KIT and 
PDGFRA may have a beneficial role in further understand-
ing of tumor biology and subsequently may help in making 
proper decisions in each individual GIST patient. Various 
types of PDGFRA and KIT mutations in GISTs are fre-
quently described in the relevant literature so far. Concerning 
the KIT gene, the mutation in exon 11 is most commonly de-
scribed, followed with the mutations in exon 9, seldom in exons 
13 and 17 8. Deletion mutation in exon 11 (codons 557 and 558) 
was linked to more aggressive clinical course of the disease 9. 
On the other hand, the PDGFRA mutations, most frequently en-
countered in exons 12, 16 and 18, are less frequent than the KIT 
mutations, but their presences is associated with favorable pa-
thologic and clinical tumor behavior 10, 11. 
Clinical studies on KIT and PDGFRA in gastric GIST 
so far have been able to prove the significance of these muta-
tions on tumor behavior, mostly reflected in disease relapse, 
metastatic potential and overall survival, although the studies 
that brought up this issue tended to have conflicting find-
ings 12. This might be due to the fact that various mutations 
can be encountered, for example in KIT exon 11, differently 
affecting tumor’s biology 13, 14. 
The aim of this study was to evaluate the significance of 
KIT and PDGFRA mutations as prognostic factors in correlation 
to metastatic potential and overall survival in the patients who 
underwent primary surgical treatment of gastric GIST. 
Methods 
This is the retrospective clinical study conducted at the 
Department for Esophagogastric Surgery, First Surgical Univer-
sity Hospital, Clinical Center of Serbia, Faculty of Medicine, 
University of Belgrade. The molecular analysis was performed 
in a genetic laboratory, at the Institute for Neurology, Clinical 
Center of Serbia, Faculty of Medicine, Belgrade. It included the 
patients who were submitted to primary curative surgical treat-
ment of gastric GIST without prior imatinib mesylate treatment, 
from November 2000 till November 2016. The Hospital Board 
and the Ethics Committee approved the study. 
A database was created by the assessment of medical 
records and it included the following: demographic and clin-
ical data, location and tumor size, type of surgical interven-
tion, pathological and immunohistochemical examination. 
The follow-up records were collected prospectively and as-
sessed the data regarding the tumor recurrence, or metastasis 
onset. The preoperative diagnostics was performed in all 
cases and it consisted of barium swallow radiography, 
esophagogastroduodenoscopy, endoscopic ultrasonography, 
computed tomography (CT) scan of thorax and abdomen. 
The pathological reports were retrospecitvelly reviewed 
with respect to the resection margins, tumor size (the largest 
diameter was taken into acount), cellularity, cell type and mitotic 
index per 50 HPF (High Power Field). The immuno-
histochemical report included immunophenotype determination 
(positivity for CD117, CD34, α-SMA, desmin, S-100). The risk 
assessment and postoperative stratification in three categories 
was performed based on the criteria recommended by the 
National Institutes of Health (NIH), depending on the tumor site, 
size and mitotic index respectively. 
The follow-up protocol included the clinical examinations 
and CT scans. The patients with the high and intermediate 
risk GIST were examined every 4 months during the first 3 
years, followed by every 6 months during the next 2 years 
and once a year thereafter. The patients with a low risk GIST 
were examined yearly during 5 years. 
Molecular analysis 
The molecular genetic analysis was performed in the 
KIT and PDGFA genes, derived from the formalin fixed par-
affin-embedded tumor samples. After the identification of 
tumor tissue, the sample sized 1 × 1 cm was chosen for the 
DNA extraction. After the paraffin removal, DNA was ex-
tracted by using the phenol-chloroform method. Isolated 
DNA was subsequently used for the mutations analysis in se-
lected exons KIT and PDGFRA genes with the direct se-
quencing method according to Sanger. The PCR amplifica-
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tion of desired regions was performed with specific primers 
(Verity Thermal Cycler, Life Technology, USA). This was 
followed by the PCR purification, and sequencing by using 
the BigDye Terminator v 3.1 Cycle Sequencing kit (Life 
Technology, USA). The sample analysis was performed by 
the capillary electrophoresis method using the ABI 3500 Ge-
netic Analyzer, and for the software data processing, the Se-
quencher program version 4.10.1. was applied. 
The presence of mutation in KIT and PDGFRA was the 
main inclusion criteria. Out of overall patient sample (n = 100), 
43 patients had mutations in KIT and PDGFRA and 2 patients 
were classified as the wild type and were the subject of further 
analysis. Remaining 55 patients, in whom the curative surgical 
treatment of gastric GIST was conducted, did not possessed a 
tissue sample of sufficient quality for the genetic analysis. Sig-
nificantly, none of the patients received KIT, so all analyses 
were performed in imatinib mesylate-naive tumor sample. 
Statistical analysis 
The data are expresed as means with percentages and 
standard deviations. The statistical correlations between dif-
ferent pathological parameters were tested by using the χ2 
test and the Fischer’s extact test. The survielance curve was 
created using the Kaplan-Meier method, and a statistical sig-
nificance was tested with the log-rank test. The level of sta-
tistical significance was set at 0.05. All analyses were per-
formed by using the statistical software SPSS version 15.0. 
Results 
Overall, the study included 45 patients, of whom 21 men, 
and 24 women, who met the inclusion criteria. The mean age of 
study population was 59.1 years (range from 23 to 84 years). 
Bleeding was the predominant symptom in the disease presenta-
tion in 22 patients, followed by the abdominal pain in 10 pa-
tients and the abdominal discomfort in 6 patients, while dys-
phagia was present in 2 patients and 1 patient had the abdominal 
palpable mass. There were 4 asymptomatic patients. 
Primary curative surgical treatment was conducted in 
all patients. Table 1 presents the range of surgical interven-
tions which were performed. There was no postoperative 
morbidity nor mortality in the study. 
After the pathological examination, 26 patients were 
classified as high risk GIST, 8 and 11 as intermediate and 
low risk, respectively, while none of the patients fulfilled the 
criteria for very low risk. The detailed clinical, pathological 
and imunohistochemistery data are given in Table 2. 
The mean length of follow-up was 61.77 months (rang-
ing from 9 to 142 months). 
 
Table 2 
Clinical and pathological characteristics of 
gastrointestinal stromal tumor (GIST) patients 
Parameters Values 
Sex, n (%)  
male 21 (49) 
female 24 (51) 
Age (years), mean (range) 59 (23–84) 
Symptoms, n (%)  
melena 20 (44) 
haematemesis 2 (4) 
abdominal pain 10 (22) 
abdominal discomfort 6 (13) 
dysphagia 2 (4) 
palpabil mass 1 (2) 
asymptomatic 4 (8) 
Tumor longest diameter (mm),  
Mean (range) 77.84 (22–210) 
Tumor dimension grups, n (%)  
≤ 2 cm 0 
> 2 ≤ 5 cm 13 (29) 
> 5 ≤ 10 cm 23 (51) 
> 10 cm 9 (20) 
Mitosis, n (%)  
≤ 5/50 HPF 24 (53) 
> 5/50 HPF 21 (47) 
Necrosis, n (%)  
absent 31 (69) 
focal  12 (27) 
spread 2 (4) 
Anaplasia, n (%)  
low 43 (96) 
high 2 (4) 
Cellulary type, n (%)  
spindele 36 (80) 
epithelioid 3 (7) 
mixed 6 (13) 
CD 117, n (%)  
- 6 (13) 
+ 39 (87) 
CD 34, n (%)  
- 6 (13) 
+ 39 (87) 
SMA, n (%)  
- 31 (69) 
+ 14 (31) 
Resection margins, n (%)  
R0 45 (100) 
R1 0 
NIH risk, n (%)  
very low 0 
low 11 (24) 
intermediate 8 (18) 
high 26 (58) 
 
Table 1 
Surgical management of the gastrointestinal stromal tumors and risk classification 
Type of surgery 
Low risk 
(n = 11) 
Intermediate risk  
(n = 8) 
High risk 
(n = 26) 
Total 
(n = 45) 
Wedge resection, n (%) 9 (20) 8 (18) 10 (22) 27 (60) 
Subtotal gastrectomy, n (%) 1 (2) 0 (0) 4 (9) 5 (11) 
Total gastrectomy, n (%) 1 (2) 0 (0) 10 (22) 11 (24) 
Distal esophagectomy and total 
gastrectomy, n (%) 
0 (0) 0 (0) 2 (5) 2 (5) 
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Table 3 
Follow-up data of gastrointestinal stromal tumor (GIST) patients 
Occurence of metastases 
Total of number of patients (45) 
n (%) 
Metastasis or local recurrence  
 intraoperative metastasis 2 (4) 
 metastasis during follow-up 9 (20) 
 local recurrence during follow-up 3 (7) 
 no metastasis / recurrences 31 (69) 
Mean time to metastasis/recurrence in months 24.83 
Current status  
 ANED 31 (69) 
 AWD 5 (11) 
 DOD 7 (16) 
 DUC 2 (4) 
ANED – alive no evidence of disease; AWD – alive with disease; DOD – died of disease; DUC – died of unrelated causes. 
 
Table 3 presents a proportion of patients with liver me-
tastasis on admission, who were submitted to surgery due to 
bleeding from the primary tumor site, the patients who de-
veloped liver metastasis and a local recurrence during the 
follow-up period, and the patients who are disease free. 
The median interval from the surgery to occurrence of me-
tastasis, or a local recurrence was 24.83 months (2–92 months). 
Two patients, who had liver metastases diagnosed intraopera-
tively, were submitted to metastasectomy, R0 resection was 
reached, and the postoperative course went uneventfully. 
Molecular analysis 
The molecular analysis showed that the genetic muta-
tions in KIT and PDGFRA were present in 43 patients, while 
2 cases were classified as the wild type GIST. A simplified 
presentation of genetic mutations in KIT and PDGFRA is 
shown in Table 4. 
Table 4 
Distribution of KIT and PDGFRA mutations 
Type of mutation 
Total of number of patients (45) 
n (%) 
KIT 37 (82) 
 Exon 9  
 insertion 1 (2) 
 deletion 2 (4) 
 point mutation 2 (4) 
 Exon 11  
 insertion 3 (7) 
 deletion 18 (45) 
 insertion-deletion 3 (7) 
 point mutation 8 (18) 
PDGFRA 6 (13) 
 Exon 12  
 deletion 1 (2) 
 Exon 16  
 point mutation 1 (2) 
 Exon 18  
 point mutation 4 (9) 
Wild type KIT/PDGFRA 2 (5) 
PDGFRA – platelet-derived growth factor receptor alpha. 
 
The KIT mutations were present in 37 patients. Out of 
those, 18 patients had deletion on exon 11, 3 patients had in-
sertion, 3 had the combination of insertion and deletion, 
while the point mutation was present in 8 of them. The exon 
9 mutations were present in 5 patients, the deletion and point 
mutation in 2, and insertion in 1 patient. The PDGFRA muta-
tions were present in 6 patients. Out of those, 4 patients had 
presence of point mutations on exon 18, while 1 had deletion 
on exon 12 and 1 the point mutation on exon 16. 
The correlation between the pathological parameters 
and types of genetic mutation was shown in Table 5. A sta-
tistically significant correlation was found between the mi-
totic rate and KIT mutations (p = 0.021). There was no statis-
tical correlation between other pathological parameters and 
analyzed genetic mutations. 
The Kaplan-Meier curve, as well as 1, 5 and 10 years of sur-
vival rates with regard to the type of mutation are presented in Fig-
ure 1. Overall survival rate for the patients with the proven KIT 
gene mutation was 71% (91%, 78% and 71% during 1, 5 and 10 
years, respectively). In the patients without these mutations overall 
survival rate was 85% (94%, 85% and 85% during 1, 5 and 10 years 
respectively). The patients with the proven PDGFRA mutations had 
the overall survival rate 100%. Both patients with the wild type mu-
tations were also alive and disease free through the follow-up pe-
riod. There were no statistically significant differences between the 
overall survival and the type of mutations (p = 0.310). 
 
Fig. 1 – Kaplan –Meier curve showing overall survival rates 
with regard to different genetic mutation type.  
PDGFRA – platelet-derived growth factor alpha. 
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Table 5 
Correlation between the pathological and molecular parameters 
KIT exon 9 mutations, n (%) KIT exon 11 mutations, n (%) PDGFRA mutations, n (%)  







Cell type             
spindle 1 (100.0) 0 (0.0) 2 (100.0) 3 (100.0) 15 (83.3) 2 (66.7) 7 (87.5) 1 (100.0) 0 (0.0) 3 (75.0) 
epitheloid 0 (0.0) 1 (50.0) 0 (0.0) 0 (0.0) 1 (5.6) 0 (0.0) 1 (12.5) 0 (0.0) 0 (0.0) 1 (25.0) 
mixed 0 (0.0) 1 (50.0) 0 (0.0) 0 (0.0) 2 (11.1) 1 (33.3) 0 (0.0) 
0.550 
0 (0.0) 1 (100.0) 0 (0.0) 
0.400 
Mitotic count             
≤ 5/50 HPF 0 (0.0) 0 (0.0) 2(100.0) 2 (66.7) 6 (33.3) 1 (33.3) 7 (87.5) 0.021 1 (100.0) 1 (100.0) 2 (50.0) 
> 5/50 HPF 1 (100.0) 2(100.0) 0 (0.0) 1 (33.3) 12 (66.7) 2 (66.7) 1 (12.5)  0 (0.0) 0 (0.0) 2 (50.0) 1.000 
Tumor necrosis             
absent 1 (100.0) 1 (50.0) 2 (100.0) 1 (33.3) 11 (61.1) 1 (33.3) 7 (87.5) 1 (100.0) 1 (100.0) 3 (75.0) 
focal 0 (0.0) 1 (50.0) 0 (0.0) 2 (66.7) 5 (27.8) 2 (66.7) 1 (12.5) 0 (0.0) 0 (0.0) 1 (25.0) 
spread 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (11.1) 0 (0.0) 0 (0.0) 
0.613 
0 (0.0) 0 (0.0) 0 (0.0) 
1.000 
Anaplasia             
low 1 (100.0) 2 (100.0) 2 (100.0) 3 (100.0) 17 (94.4) 3 (100.0) 8 (100) 1 (100.0) 1 (100.0) 4 (100.0) 
high 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.6) 0 (0.0) 0 (0.0) 1.000 0 (0.0) 0 (0.0) 0 (0.0) 1.000 
NIH score             
very low 0 (0.0) 0 (0.0) 0 (0.0) 1 (33.3) 4 (22.2) 0 (0.0) 4 (50.0) 0 (0.0) 1 (100.0) 1 (25.0) 
low 0 (0.0) 0 (0.0) 1 (50.0) 1 (33.3) 2 (11.1) 1 (33.3) 2 (25.0) 1 (100.0) 0 (0.0) 1 (25.0) 
intermediate 0 (0.0) 1 (50.0) 1 (50.0) 1 (33.3) 1 (5.6) 1 (33.3) 1 (12.5) 0 (0.0) 0 (0.0) 0 (0.0) 
high 1 (100.0) 1 (50.0) 0 (0.0) 0 (0.0) 11 (61.1) 1 (33.3) 1 (12.5) 
0.145 
0 (0.0) 0 (0.0) 2  (50.0) 
1.000 
*Ins – insertion; Del – deletion; PM – point mutation; NIH – National Institutes of Health. 
For other abbreviations see under Table 4. 
 
Discussion 
The results of this study implicated that the KIT gene 
mutations are the most common type of mutation in gastric 
GIST. Although the clinical relevance of these mutations in 
our patient population was not clearly shown, in the discus-
sion bellow we will try to make a thorough analysis and 
draw out relevant conclusion. 
In the overall patient sample KIT and PDGFRA mutations 
were present in 45% of patients, predominantly KIT mutations 
in exon 11, while PDGFRA mutations were observed in 6 pa-
tients. These frequencies are lower than those noted in the litera-
ture reports so far, where the occurrence of KIT mutations was 
reported to be around 80%, and PDGFRA approximately about 
10%. This can be explained by the retrospective nature of the 
study and the possibility that some of tumor samples were not 
preserved sufficiently to contain DNA suitable for further analy-
sis. Yet, the overall distribution of molecular changes in this 
study population, reflected in the KIT versus PDGFRA muta-
tions ratio as well as frequencies of mutation types, is in accor-
dance to the literature results 15. 
The KIT mutation was the predominant type of muta-
tion in our study and the leading type of mutation was dele-
tion in exon 11. This is in concordance with the report of 
Joensuu et al. 16, who based their study on an analysis of 11 
literature reports concerning the KIT and PDGFRA muta-
tions in GIST. The authors confirmed that the KIT mutations 
in exon 11 were the most common type of mutation, and pre-
sented in 293 out of 301 analyzed patients. Deletion was 
most common type of mutation, presented in 43% of pa-
tients. Concerning the relation of this specific mutation and 
other pathological parameters of GIST, our study showed 
that the presence of this mutation had a strong statistical cor-
relation with the higher mitotic index. However, there was 
no correlation with other pathological parameters. The re-
sults of published studies shows that KIT mutations in exon 
11 can be linked with more aggressive tumor behavior 17, 18. 
Capelli et al. 19 showed that the patients with gastric GIST 
who had the KIT mutations, were presented with worse pa-
thological parameters, such as tumor necrosis, spindle cellu-
larity, tumor size and mitotic index. Similar results were 
noted by Schaefer et al. 20. 
The PDGFRA mutations were by far less present in our 
study than the KIT mutations, which is concordance with 
other literature reports being around 6%. The most common 
type of PDGFRA mutation noted in our study was the point 
mutation on exon 18. There was no statistical correlation be-
tween these molecular changes and the analyzed pathological 
parameters. Lasota and Miettinen 14 found that the majority 
of GIST patients with the presence of PDGFRA mutation 
had predominantly the epitheloid type of tumor, with the low 
mitotic index and benign clinical course. 
In our study, the overall survival rate among the pa-
tients who had the KIT mutations during the 10-year follow-
up was 71%, while in those GIST patients with the PDGFRA 
mutations there was no mortality in the follow-up period. Al-
though there is a tendency towards better overall survival in 
the group of patients with the PGFRA mutations, a statistical 
significance was not reached probably due to a small sample 
size inside this group. Our study involved the patients who 
did not receive any prior imatinib mesylate therapy. Rossi et 
al. 21 published their results concerning imatinib-naive GIST 
patients with regard to a tumor mutational status and con-
firmed that the KIT mutations were the independent prognos-
tic factors of poor overall survival. The authors also identi-
fied several groups according to the mutation status and they 
were those with an increased risk of tumor recurrence and 
metastasis. Those with the greatest malignant potential had 
mutations in KIT exon 9 and 11, and PDGFRA in exon 18 
apart from D842V. 
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Limitations of this study include a relatively small sam-
ple of patients and the retrospective method. 
Conclusion 
A risk stratification for gastric GIST is well- established 
and based on clinically proven classifications based on the 
tumor site, size and mitotic rate. The recognition and as-
sessment of KIT and PDGFRA mutations in these tumors 
may play a significant role as an additional factor in the risk 
stratification, disease prognosis, but may be important to 
identify the patients who are at the highest risk for disease 
recurrence. 
 
R E F E R E N C E S
1. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu 
VR. Global epidemiology of gastrointestinal stromal tumours 
(GIST): A systematic review of population-based cohort stud-
ies. Cancer Epidemiol 2016; 40: 39–46.  
2. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal 
stromal tumors. J Clin Oncol 2004; 22(18): 3813–25.  
3. Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gus-
tavsson B, et al. Gastrointestinal stromal tumors: the incidence, 
prevalence, clinical course, and prognostication in the prei-
matinib mesylate era--a population-based study in western 
Sweden. Cancer 2005; 103(4): 821–9. 
4. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, 
et al. Diagnosis of gastrointestinal stromal tumors: A consen-
sus approach. Hum Pathol 2002; 33(5): 459–65. 
5. Lasota J, Miettinen M. KIT and PDGFRA mutations in gastro-
intestinal stromal tumors (GISTs). Semin Diagn Pathol 2006; 
23(2): 91–102. 
6. Stenman G, Eriksson A, Claesson-Welsh L. Human PDGFA re-
ceptor gene maps to thesame region on chromosome 4 as the 
KIT oncogene. Genes Chromosomes Cancer 1989; 1(2): 155–8. 
7. Pawson T. Regulation and targets of receptor tyrosine kinases. 
Eur J Cancer 2002; 38 Suppl 5: S3–10. 
8. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe 
DN, et al. Structural basis for the autoinhibition and STI-571 
inhibition of c-Kit tyrosine kinase. J Biol Chem 2004; 279(30): 
31655-63. 
9. Martín J, Poveda A, Llombart-Bosch A, Ramos R, López-Guerrero 
JA, García del Muro J, et al. Deletions affecting codons 557-558 
of the c-KIT gene indicate a poor prognosis in patients with 
completely resected gastrointestinal stromal tumors: a study by 
the Spanish Group for Sarcoma Research (GEIS). J Clin On-
col 2005; 23(25): 6190–8.  
10. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Jo-
seph N, et al. PDGFRA activating mutations in gastrointestinal 
stromal tumors. Science 2003; 299(5607): 708–10. 
11. Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. A 
great majority of GISTs with PDGFRA mutations represent 
gastric tumors of low or no malignant potential. Lab Invest 
2004; 84(7): 874–83. 
12. Baskin Y, Kocal GC, Kucukzeybek BB, Akbarpour M, Kayacik N, 
Sagol O, et al. PDGFRA and KIT Mutation Status and Its As-
sociation With Clinicopathological Properties, Including 
DOG1. Oncol Res 2016; 24(1): 41–53. 
13. Kim TW, Lee H, Kang YK, Choe MS, Ryu MH, Chang HM, et al. 
Prognostic significance of c-kit mutation in localized gastroin-
testinal stromal tumors. Clin Cancer Res 2004; 10(9): 3076–81.  
14. Lasota J, Miettinen M. Clinical significance of oncogenic KIT 
and PDGFRA mutations in gastrointestinal stromal tumours. 
Histopathology 2008; 53(3): 245–66. 
15. Daniels M, Lurkin I, Pauli R, Erbstösser E, Hildebrandt U, Hellwig 
K, et al. Spectrum of KIT/PDGFRA/BRAF mutations and 
Phosphatidylinositol-3-Kinase pathway gene alterations in gas-
trointestinal stromal tumors (GIST). Cancer Lett 2011; 312(1): 
43–54.  
16. Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank L, 
et al. KIT and PDGFRA mutations and the risk of GI stromal 
tumor recurrence. J Clin Oncol 2015; 33(6): 634–42. 
17. Andersson J, Bümming P, Meis-Kindblom JM, Sihto H, Nupponen N, 
Joensuu H, et al. Gastrointestinal stromal tumors with KIT ex-
on 11 deletions are associated with poor prognosis. Gastroen-
terology 2006; 130(6): 1573–81. 
18. Wardelmann E, Losen I, Hans V, Neidt I, Speidel N, Bierhoff E, et 
al. Deletion of Trp-557 and Lys-558 in the juxtamembrane 
domain of the c-kit protooncogene is associated with metas-
tatic behavior of gastrointestinal stromal tumors. Int J Cancer 
2003; 106(6): 887–95.  
19. Capelli L, Petracci E, Quagliuolo V, Saragoni L, Colombo P, Mor-
gagni P, et al. Italian Gastric Cancer Research Group (GIRCG). 
Gastric GISTs: Analysis of c-Kit, PDGFRA and BRAF muta-
tions in relation to prognosis and clinical pathological charac-
teristics of patients - A GIRCG study. Eur J Surg Oncol 2016; 
42(8): 1206–14. 
20. Schaefer IM, Delfs C, Cameron S, Gunawan B, Agaimy A, Ghadimi 
BM, et al. Chromosomal aberrations in primary PDGFRA-
mutated gastrointestinal stromal tumors. Hum Pathol 2014; 
45(1): 85–97. 
21. Rossi S, Gasparotto D, Miceli R, Toffolatti L, Gallina G, Scaramel E, 
et al. KIT, PDGFRA, and BRAF mutational spectrum impacts 
on the natural history of imatinib-naive localized GIST: a pop-
ulation-based study. Am J Surg Pathol 2015; 39(7): 922–30. 
 
Received on February 5, 2018. 
Revised on March 1, 201. 
Accepted on March 11, 2018. 
Online First March, 2018. 
 
